A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion

作者：Carolina M. Larrain, Jack H. Victory, Priyanka Prakash Desai, Lindsay R. Friedman, H. Stepp, Robynne Ashe, Kirsten Remmert, Surajit Sinha, Emily C. Smith, Nicole Russell, Tracey Pu, Alyssa V. Eade, Justine F. Burke, Jason Ho, Michael B. Yaffe, David Erwin Kleiner, Keith Thomas Schmidt, William Douglas Figg, Jonathan M. Hernandez · 发表于：JCI Insight · 年份：2025 · DOI：10.1172/jci.insight.199200 · 被引用次数：2 · 研究领域：Multiple Myeloma Research and Treatments、Ubiquitin and proteasome pathways、Protein Degradation and Inhibitors

Targeting tumors with proteosome inhibitors has demonstrated antitumor activity and has been successfully translated to the clinic for patients with multiple myeloma. However, in patients with solid tumors, treatment with proteosome inhibitors as single agents has consistently failed to yield meaningful responses. In our study, we investigate the potential of hepatic artery infusion pump delivery of carfilzomib, to continuously direct a large dose to the tumor with least hepatic toxicity.